BLASUBCUTANEOUSINJECTABLE
Approved
Aug 2005
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
FOLLISTIM AQ is a recombinant follicle-stimulating hormone (FSH) used to stimulate ovarian follicle development in assisted reproductive technology (ART) and infertility treatment. Administered as a subcutaneous injection, it mimics the body's natural FSH to promote egg production in women undergoing fertility procedures.
LOE Approaching
Moderate competitive pressure (30/100) suggests established market position with consolidation underway; expect smaller, defensive team focused on retention and lifecycle extension.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on FOLLISTIM AQ offers stable, specialized career experience in reproductive health and fertility—a niche but loyal market segment. However, LOE approaching means career growth depends on executing defensive strategies and building expertise in biosimilar management and patient retention rather than market expansion.
Brand ManagerMedical Science Liaison (MSL)
Worked on FOLLISTIM AQ at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.